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Summary. This study was designed to test whether the selec- 
tive bradycardic effects of zatebradine (UL-FS 49) were al- 
tered in the setting of chronic mild left ventricular dysfunc- 
tion secondary to a myocardial infarction. We therefore 
administered four doses of UL-FS 49 at 15-min intervals (cu- 
mulative doses of 10, 30, 100, and 300 p~g/kg) to eight normal 
conscious pigs and to seven pigs in which the left circumflex 
coronary artery was occluded 3 weeks previously. Left ven- 
tricular dysfunction in this second group of animals was 
manifested by an increase in left ventricular end-diastolic 
pressure (LVEDP 11 -+ 2 mmHg vs. 7 -+ 1 mmHg, respec- 
tively; p < 0.05) and a decrease in LVdP/dtm~ (3020 - 210 
mmHg vs. 3720 - 210 mmHg, respectively; p < 0.05). The 
results showed that UL-FS 49 was equally effective in reduc- 
ing heart rate in both groups of animals [from 126 -+ 4 to 95 
- 2 beats/min and from 140 -+ 5 to 98 - 6 beats/min for the 
normal animals and for the animals with a chronic myocar- 
dial infarction (MI), respectively]. The duration of left ven- 
tricular systole was not affected, but the duration of diastole 
was prolonged from 290 -+ 10 msec to 420 _+ 20 msec in the 
normal animals and from 250 - 10 msec to 430 -+ 30 msec in 
the animals with MI (both p < 0.05). Up to 100 ~tg/kg UL-FS 
49 did not affect arterial blood pressure, whereas LVdP/dtma~ 
and cardiac output decreased by less than 10% in either 
group. With the highest dose there were decreases in cardiac 
output (20%) and LVdP/dtma~ (15%) and a 5-6 mmHg increase 
in left ventricular end-diastolic pressure in both groups. The 
data suggest hat UL-FS 49 in doses up to 100 ~tg/kg may also, 
in the setting of chronic mild left ventricular dysfunction, 
be an attractive agent when heart rate has to be reduced 
selectively. 
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A reduction in heart  rate will improve myocardial 
oxygen balance by both reducing oxygen demand and 
improving oxygen supply, in part icular of the suben- 
docardial layers, the most vulnerable area of the myo- 
cardium. The above are the most important reasons 
for the anti ischemic effects of selective bradycardic 
agents in the t reatment  of acute experimental  myo- 
cardial ischemia [1-4]. Hoffman [5] and Canty et al. 
[6] recent ly pointed out that selective bradycardic 
agents may also be useful to reverse the adverse ef- 
fect of tachycardia on the lower limit of subendocar- 
dial autoregulation. The last group of investigators 
observed that increasing the heart  rate in dogs from 
100 to 200 beats/rain increased the minimal coronary 
perfusion pressure needed to ensure normal suben- 
docardial perfusion by 60% [6]. The mechanisms re- 
sponsible for this increase in minimal coronary per- 
fusion pressure are believed to be related to the 
tachycardia- induced myocardial  oxygen consumption, 
which increases autoregulated coronary flow [7] and 
the tachycardia- induced r uction in diastolic time per 
minute, which decreases maximal coronary flow [8]. 
In normal hearts a tachycardia-induced reduction in 
coronary flow reserve will not lead to subendocardial 
ischemia, but if coronary flow reserve is already im- 
paired, for instance, due to hypertrophy, myocardial 
ischemia may ensue when heart  rate increases. 
UL -FS  49 (1,3,4,5-tetra hydro-7,8-dimethoxy-3[3- 
[2-(3,4-dimethoxyphenyl)-ethyl]-methylamino] propyl - 
2H-3-benzazepin-2-on-hydrochloride; F g. 1) is a so- 
called specific bradycardic agent, which lowers heart 
rate by a mechanism other than beta-adrenoceptor or 
calcium-channel blockade [9,10], although there are 
structural  similarit ies with verapamil. Similar to alini- 
dine, the mode of action of UL -FS  49 may be by an 
effect on anionic channels [11] or by the If channel 
[12,13]. UL -FS  49 has been shown to predominantly 
reduce heart  rate [9,10] and thereby improves the 
perfusion and function of acutely ischemic myocar- 
dium [2-4]. The effects of UL -FS  49 in animals with 
chronic left ventr icular dysfunction have not yet been 
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Fig. I. The chemical structure of zatebradine (UL-FS 49). 
studied. We have, however, shown that in conscious 
pigs chronic left ventricular dysfunction may alter the 
quantitative, as well as the qualitative, ffects of car- 
diovascular drugs [14,15]. Furthermore, when left 
ventricular function is chronically impaired, a reduc- 
tion in heart rate by ~-adrenoceptor blockade often 
leads to a further deterioration fcardiovascular per- 
formance due to unwanted negative inotropy [15]. In 
the present study we therefore valuated the cardio- 
vascular effects of UL-FS 49 in conscious pigs with 
a 3-week-old myocardial infarction and compared the 
results to those obtained in a group of pigs with nor- 
mal hearts, in order to establish whether the cardio- 
vascular effects of UL-FS 49, in particular on diastolic 
perfusion time, were affected by the chronic left ven- 
tricular dysfunction. 
Mater ia l s  and  Methods  
Surgical procedures 
The experimental procedures were approved by the 
Committee on Animal Experiments of the Erasmus 
University Rotterdam, and complied to the guidelines 
for the use and care of experimental nimals as put 
forward by the Council of the American Physiological 
Society [DHEW Publication No. (NIH) 80-23, 1980]. 
After an overnight fast, 20 crossbred Landrace x
Yorkshire pigs of either sex (19-21 kg at the time 
of surgery), pretreated with 600 mg of a mixture of 
procaine penicillin-G and benzathine penicillin-G intra- 
muscularly (Duplocillin, Gist-Brocades NV, Delft, 
The Netherlands), were sedated with an intramuscu- 
lar injection of 30 mg/kg ketamine HCL (Aeskoket, 
Aesculaap BV, Boxtel, The Netherlands). Subse- 
quently the animals were intubated and mechanically 
ventilated with a mixture of oxygen and nitrous oxide 
(1:2) to which 1-4% (v/v) enflurance was added. Un- 
der sterile conditions, a jugular vein and a common 
carotid artery were cannulated for infusion of drugs 
or  solvent, and for the measurement of arterial blood 
pressure, respectively. The chest was opened via the 
third left intercostal space, and an electromagnetic 
flow probe (Skalar, Delft, The Netherlands) was posi- 
tioned around the ascending aorta for the measure- 
ment of aortic blood flow. The heart was exposed via 
the fifth intercostal space, and a Konigsberg pressure 
transducer (Konigsberg Instrument Inc., Pasadena, 
CA) was implanted into the left ventricle of the heart 
through its apex for recording of left ventricular pres- 
sure. The left atrium was cannulated for the recording 
of left atrial pressure, which, together with the arte- 
rial blood pressure, was used for calibration of the 
Konigsberg transducer signals. 
In 12 animals the proximal segment of the left cir- 
cumflex coronary artery (LCXCA) was permanently 
ligated for the induction of a myocardial infarction. 
Serious ventricular arrhythmias ( ustained ventricu- 
lar tachycardia or ventricular fibrillation) were 
treated with immediate DC countershock. After 30 
minutes the chest was closed and the wires were tun- 
nelled subcutaneously to the back, and the animals 
were allowed to recover from surgery. 
The animals received aily intravenous doses of 500 
mg amoxicilline (Clamoxil, Beecham Farma BV, Am- 
stelveen, The Netherlands) and, during the first week 
only, kanamycin 500 mg (Kanymex, Gist Brocades 
NV, Delft, The Netherlands) to prevent infection. 
Catheters were flushed daily with an isotonic saline 
solution containing 500 IU/ml heparin. During the 
first 3 weeks of the postoperative recovery period, the 
animals were adapted to the laboratory facilities (8-10 
sessions), while hemodynamic parameters were moni- 
tored. The experimental protocols were executed 
when systemic hemodynamics and arterial blood gases 
remained stable for at least 1 hour, usually 3 weeks 
after instrumentation. All measurements were done 
while the animals were quietly resting in a con- 
straining jacket. 
Mortality 
All eight animals with the intact coronary circulation 
could be used for the study. From the 12 pigs in which 
the left circumflex coronary artery was occluded, four 
animals died suddenly during the postoperative p - 
riod, most likely secondary to a ventricular arrhyth- 
mia. One animal was excluded from the study because 
of the failure of the electrical transducers. 
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Experimental protocols 
After baseline hemodynamic measurements were ob- 
tained, each animal received four bolus infusions of 
UL-FS 49 of 10, 20, 70, and 200 ~Lg/kg (cumulative 
doses of 10, 30, 100, and 300 ~Lg/kg) or the solvent of 
UL-FS 49 at 15-minute intervals. At the end of each 
15 minute period, all hemodynamic measurements 
were repeated before the next dose was administered. 
The duration of systole and diastole were determined 
from the arterial blood pressure recordings. The nadir 
of diastolic arterial blood pressure was taken as the 
onset and the occurrence of the incisura as the end of 
the left ventricular ejection. The experiments with 
the drug and the solvent were separated by at least 
24 hours. Volumes of the solvent corresponded with 
those administered during the UL-FS 49 infusions. 
Drugs 
UL-FS 49 was supplied by Dr. Karl Thomae GmbH 
(Biberach an der Riss, Germany). The drug was dis- 
solved in saline (0.9% NaC1 w/v) to a concentration f 
10 ~g/kg/ml. 
Statistical analysis 
All data have been presented as mean _+ SEM. Differ- 
ences between the baseline values of the two groups of 
animals were evaluated using the unpaired Student's 
t-test (two tailed). Statistical significance of drug- 
induced changes was determined by comparison to the 
solvent-induced changed from the same group. A 
Bonferroni correction was used because of multiple 
measurements. Statistical significance was accepted 
for a probability less than 5%. 
Results 
Blood gases 
Arterial blood gases of the normal animals and the 
animals with chronic left ventricular dysfunction did 
not differ and were within the limits of those reported 
earlier for conscious pigs [15], measured with an 
ABL-3 (Radiometer, Copenhagen, Denmark): pH 7.42 
-+ 0.02, p02 75 - 3 mmHg, and pCO~ 40 - 2 mmHg. 
Baseline values of systemic hemodynamic of
normal pigs and pigs with the infarctions 
The baseline values of the animals with a chronically 
occluded left circumflex coronary artery showed some 
significant differences compared with normal con- 
scious animals (Tables 1 and 2). In the former, heart 
rate was 10% higher and LVdP/dtma x was 20% lower 
than in normal animals. The differences in mean arte- 
rial blood pressure and stroke volume were not sig- 
nificantly different. Left ventricular filling pressure, 
however, was significantly higher in the animals with 
chronic left circumflex coronary artery occlusion (14 
-+ 2 vs. 9 -+ 1 mmHg, p < 0.05). Table 1 also shows 
that the systemic hemodynamic parameters emained 
stable in both groups of animals during the infusion of 
the solvent. 
Table 1. Stability of systemic hemodynamic parameters during solvent infusion of eight normal conscious pigs (N) and in seven 
conscious pigs with a 3-week-old myocardial infarction (MI) 
Saline (ml) 
Baseline 1 2 7 20 
HR N 121 _+ 9 123 _+ 11 121 _+ 11 120 _+ 12 122 -+ 11 
MI 131 -+ 4 130 _+ 4 130 -+ 3 129 _+ 4 131 _+ 4 
CO N 2.64 _+ 0.05 2.63 -+ 0.05 2.63 -+ 0.05 2.59 -+ 0.07 2.61 -+ 0.04 
MI 2.52 _+ 0.10 2.52 -+ 0.11 2.51 _+ 0.10 2.50 _+ 0.10 2.50 -+ 0.10 
SAP N 129 _+ 4 126 -+ 4 126 _+ 3 127 _+ 3 130 -+ 5 
MI 119 -+ 4 119 _+ 4 121 -+ 4 120 -+ 4 119 -+ 5 
MAP N 99 -+ 4 97 -+ 4 98 -+ 4 99 -+ 4 100 -+ 4 
MI 97 -+ 4 97 -+ 4 99 -+ 4 97 -+ 4 98 -+ 5 
DAP N 73-+5 71-+6 72+5 73-+4 74+5 
MI 76 -+ 2 77 ÷ 2 78 -+ 3 77 -+ 2 78 -+ 3 
LVdP/dtm~x N 3640 _+ 270 3520 _+ 280 3420 _+ 250 3510 _+ 350 3680 _+ 310 
MI 2720 -+ 200 a 2680 _+ 170 2820 -+ 190 2720 -+ 200 2670 -+ 220 
LVEDP N 9-+ 1 9-+ 1 9-+ 1 9-+ 1 9-+ 1 
MI 14 + 2 a 14 _+ 2 14 -+ 2 15 -+ 2 14 _+ 2 
SV N 22.2 -+ 1.9 22.0 -+ 2.4 22.4 -+ 2.3 22.1 -+ 2.1 22.1 -+ 2.1 
MI 19.2 -+ 0.8 19.5 -+ 0.8 19.3 _+ 0.9 19.5 _+ 0.9 19.1 _+ 0.9 
HR = heart rate (beats/min); CO = cardiac output (1/rain); SAP, 
(mmHg), respectively; LVdP/dtma x = maximal rate of rise of left 
pressure (mmHg); SV = stroke volume (ml). 
~p < 0.05 versus normal pigs (for baseline measurements only). 
MAP, and DAP are systolic, mean, and diastolic arterial blood pressure 
ventricular pressure (mmHg/s); LVEDP - left ventricular end-diastolic 
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Table 2. Systemic hemodynamic effects of UL-FS 49 in eight normal conscious pigs (N) and in seven conscious pigs with a 
3-week-old myocardial infarction (MI) 
UL-FS 49 (~g/kg) 
Baseline 10 20 70 200 
Total dose 0 10 30 100 300 
HR N 126 ± 4 125 -+ 4 120 -+ 45 114 _+ 4 b 95 -+ 25 
MI 140±4 138-+5 133±6 b 117-+5 b 98±65 
CO N 2.65 ± 0.11 2.55 -+ 0.125 2.49 --_ 0.12 b 2.45 ± 0.18 b 2.19 ± 0.125 
MI 2.58 ± 0.11 2.54 ± 0.10 2.46 ± 0.10 b 2.36 --+ 0.10 b 2.02 ± 0.205 
SAP N 122 ± 5 122 ± 5 121 -+ 4 122 ± 4 124 -+ 6 
MI 114 -+ 5 113 ± 5 114 ± 5 117 ± 5 115 ± 4 
MAP N 99±4 100±4 98±3 97±3 95±4 
MI 93±4 93-+4 94±4 94±4 90-+3 
DAP N 74-+6 77±5 73±5 70±5 66±7 
MI 73±4 71_+4 73_+4 72±3 66±3 
LVdP/dtmax N 3720 ± 210 3680 ± 230 3510 ± 2305 3420 ± 2805 3140 ± 280 b 
MI 3020 -+ 210 a 2740 ± 250 b 2790 ± 2405 2720 ± 220 b 2570 ± 290 b 
LVEDP N 7 ± 1 8 _+ 1 8 _+ 1 9 _+ 1 b 12 ± 15 
MI 11 ±2 a 12-+2 11 ±2 13-+2 16±3 b
SV N 21.7 ± 1.2 21.2 -+ 1.6 21.4 ± 1.5 22.5 ± 1.8 23.6 ± 1.3 
MI 18.6 ± 1.4 18.5 _+ 1.2 18.3 ± 1.2 20.0 ± 1.05 20.7 ---- 1.4 
HR = heart rate (beats/min); CO = cardiac output (1/min); SAP, MAP, and DAP are systolic, mean, and diastolic arterial blood pressure 
(mmHg), respectively; LVdP/dtma x = maximal rate of rise of left ventricular pressure (mmHg/s); LVEDP = left ventricular end-diastolic 
pressure (mmHg); SV = stroke volume (ml). 
ap < 0.05 versus normal pigs (for baseline measurements only); bp < 0.05 versus baseline. 
Data have been presented as mean -+ SEM. 
Cardiovascular Effects of UL-FS 49 
Table 2 shows that UL-FS 49 was at least as effective 
in reducing heart rate in the animals with the in- 
farction as in normal animals. As a matter of fact, 
after the administration f 100 Ixg/kg (total dose), the 
reduction in the animals with the infarction was 
slightly larger (23 -+ 3 beats/min) than in normal ani- 
mals (12 -+ 2 beats/rain, p < 0.05). At other doses, the 
reduction in heart rate was, however, very similar. 
Cardiac output decreased by less than 10% in both 
groups until infusion of a cumulative dose of 300 ~g/ 
kg, which caused cardiac output to decrease by ap- 
proximately 20% in both groups. At any dose, the 
decrease in heart rate was larger than the decrease 
in cardiac output, and it therefore follows that stroke 
volume increased (10-15% at the highest dose). Mean 
arterial blood pressure was not affected in either 
group over the entire dose range, which indicates that 
peripheral vasoconstriction counterbalanced the effect 
of cardiac output on mean arterial blood pressure 
at the highest dose. LVdP/dtmax decreased in both 
groups by less than 10% until the last dose was admin- 
istered. 
During baseline conditions, the duration of systole 
was the same for both groups of animals, but the dura- 
tion of diastole was significantly reduced in animals 
with the infarction (Figure 2). The bradycardic action 
of UL-FS  49 had no effect on the duration of systole in 
either group. The duration of diastole was, however, 
significantly prolonged in a dose-dependent manner in 
both groups of animals (up to 130 -+ 20 msec in the 
normal animals and up to 180 -+ 30 msec in the animals 
with the infarctions). 
Discuss ion  
In patients with stable angina pectoris and normal eft 
ventricular function, selective bradycardic agents of- 
fer only a limited advantage above ~-adrenoceptor an- 
tagonists, e.g., where the effects on other organs 
(lungs, liver, thyroid) have to be avoided. However, in 
patients with left ventricular dysfunction, the direct 
effects on the heart may become more important. 
After a myocardial infarction, the unaffected part of 
the left ventricle has to compensate for the loss in 
contractile function of the infarcted segment. This 
may lead to compensatory h pertrophy, which results 
in a decreased coronary flow reserve. Both ~-adreno- 
ceptor antagonists and selective bradycardic agents, 
by increasing the diastolic perfusion period, may im- 
prove coronary perfusion. On the other hand, the neg- 
ative inotropic effects of ~-adrenoceptor antagonists 
may interfere with systolic function, leading to the 
need for further adaptive mechanisms, uch as ven- 
tricular dilatation, which in itself decreases ubendo- 
cardial perfusion [16]. 
Occlusion of the left circumflex coronary artery in 
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Fig. 2. Effect of UL-FS 49 on the duration of left ventricular 
systole and on the duration of diastole in eight normal con- 
scious pigs ([1) and in seven pigs with a 3-week occlusion of 
the left circumflex coronary artery (m). The figure illustrates 
that UL-FS 49 had no effect on the duration of systole but 
prolonged the duration of diastole to the same extent in both 
groups of animals. +p < 0.05 versus normal conscious pigs 
[only for predrug data (0)]. *p < 0.05 versus predrug data. 
The bars indicate the SEM. 
pigs leads to an infarct size of at least 15% of the left 
ventricle [14] and to hypertrophy of the left ventricu- 
lar anterior wall and septum. Therefore, it may serve 
as an appropriate model to compare the effects of 13- 
adrenoceptor antagonists and selective bradycardic 
agents on global left ventricular function. 
The most important finding of the present study is 
that UL-FS 49 reduced heart rate in conscious pigs 
with chronic mild left ventricular dysfunction to the 
same extent as in normal pigs, without adversely af- 
fecting cardiac performance. This is important as we 
have earlier shown that the effects of several drugs 
were modified when tested in the same model. We 
have, for example, shown that the positive inotropic 
actions of the phosphodiesterase inhibitor pimobendan 
were attenuated and that the depressant effects of 
propranolol become more apparent in animals with 
chronic left ventricular dysfunction when compared to 
the effects in normal animals [14,15]. On the other 
hand, the calcium-channel blockers nisoldipine and el- 
godipine, which had no effect on left ventricular end- 
diastolic pressure in normal conscious animals, caused 
a lowering of the elevated left ventricular pressures in 
the animals with chronic left ventricular dysfunction 
[14,15]. 
UL-FS 49 had no effect on the duration of left ven- 
tricular systole, in either group of animals. The pro- 
longation of the RR interval was therefore caused by 
a prolongation of the duration of diastole. The finding 
that UL-FS 49, amongst others, had no effect on the 
duration of systole implies that the drug does not re- 
duce the myocardial oxygen demand per heart beat, 
although it will lower the myocardial oxygen demand 
per minute by reducing the number of systoles per 
minute. The prolongation of the duration of diastole 
per heart beat (47%) or per minute (11%) is therefore 
probably the most important mechanism for the anti- 
ischemic actions of UL-FS 49 [2-4]. 
The negative chronotropic properties of UL-FS 49 
have also been studied in conscious dogs [2-4]. It is 
noteworthy that in this last species three times higher 
doses than used in pigs were needed to accomplish 
similar reductions in heart rate. Furthermore, in 
these studies in dogs the reductions in heart rate were 
accompanied by increases (significant or nonsignifi- 
cant) in LVdP/dtm~ x [2-4], whereas in pigs we found 
a small but significant decrease in LVdP/dtmax. The 
reason for this discrepancy between the two species 
cannot be easily assessed. Nevertheless, in both anes- 
thetized and conscious pigs the relation between the 
reduction in heart rate and in LVdP/dtma x is more fa- 
vorable for UL-FS 49 than for its congener falipamil 
[17] or alinidine [18,19], two other so-called specific 
bradycardic agents. We also noticed that falipamil and 
alinidine both decreased LVdP/dtmax dose depen- 
dently when heart rate was fixed by atrial pacing and 
that the magnitude of these changes were very similar 
during pacing and normal sinus rhythm [17,19]. This 
last observation is most likely explained by the obser- 
vation that, at least in anesthetized pigs, LVdP/dtmax 
is not very sensitive to changes in heart rate in the 
range of 100-150 beats/min [20]. In three preliminary 
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Table 3. Systemic hemodynamic effects of UL-FS 49 in three normal anesthetized pigs during atrial pacing at 110 beats/min 
Baseline 
prepacing UL-FS 49 (~tg/kg) Pacing off 
Total dose 0 0 10 30 100 300 
HR 101-+2 110± 1 110± 1 110± 1 110± 1 110± 1 74-+3 a
CO 2.0 -+ 0.2 2.1 ± 0.2 2.1 ± 0.2 2.0 ± 0.2 2.0 ± 0.3 2.1 ± 0.3 1.8 ± 0.2 
MAP 97±2 99-+2 102-+5 100-+5 100-+7 104±9 89-+ 11 
LVdP/dtm~ 2420 ± 280 2220 ± 330 2250 ± 370 2200 ± 340 2160 ± 360 2210 ± 420 2300 +- 370 
SV 20±2 19±2 19±2 18±2 18±2 19±2 24- -2  a 
HR = heart rate (beats/min); CO = cardiac output (1/min); MAP = mean arterial blood pressure (mmHg); LVdP/dtm~ x = maximal rate of 
rise of left ventricular pressure (mmHg/s); SV = stroke volume (ml). 
Data have been presented as mean -+ SEM. 
ap < 0.05 versus baseline prepacing. 
experiments in anesthetized pigs, we have observed 
that UL-FS 49 did not significantly decrease LVdP/ 
dtmax, when heart rate was kept constant by atrial 
pacing at 110 bpm. (Table 3). It thus appears that 
UL-FS 49 exerts considerably less negative inotropic 
effects than, for instance, alinidine or falipamil, when 
heart-rate associated changes in myocardial contrac- 
tility are excluded. 
As was discussed above, ~-adrenoceptor antago- 
nists may also ameliorate myocardial ischemia by a 
reduction in heart rate. A disadvantage of this class 
of drugs is that they can substantially decrease myo- 
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Fig. 3. Relation between changes in heart rate and stroke vol- 
ume in normal conscious pigs and in conscious pigs with 
chronic left ventricular dysfunction during the ad~inistration 
of UL-FS 49 (© and 0, respectively) and propranolol ([B and 
m, respectively). Notice that propranolol and UL-FS 49 had 
opposite ffects on stroke volume. The data on propranolol 
have been reported before [15]. 
cardial contractility. We have earlier shown that in 
animals with a 4-week-old myocardial infarction, pro- 
pranolol at a dose (0.5 mg/kg) that lowered heart rate 
by 23% reduced LVdP/dtma x by 32% [15]. With UL-FS 
49 we found that a 30% lowering of heart rate reduced 
LVdP/dtmax by only 12% (Table 2). Taking into ac- 
count that LVdP/dtma x not only depends on myocar- 
dial contractility but also on heart rate and afterload, 
we like to conclude that the negative inotropic effects 
of UL-FS 49 are negligible at doses up to 300 ~g/kg, 
which is most likely the major reason that UL-FS 49 
and propranolol have opposite ffects on stroke vol- 
ume (Figure 3). As discussed by Indolfi et al. [4], re- 
duction of heart rate by UL-FS 49 has also the advan- 
tage over ~-adrenoceptor blockade because UL-FS 49 
does not cause unmasking ofa-adrenergic constriction 
in the large coronary vessels [21,22]. 
We conclude that, in light of the absence of a de- 
pression of cardiovascular performance, the data pre- 
sented in this study suggest that UL-FS 49 could be 
an attractive agent to selectively reduce heart rate 
during chronic mild left ventricular dysfunction. Fur- 
ther studies evaluating the effects of chronic treat- 
ment of UL-FS 49, therefore, appear to be the logical 
next approach. 
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